Cell News and Research

RSS

New review finds scant scientific evidence supporting use of cannabinoids in rheumatic diseases

Although there are anecdotal reports indicating that cannabinoids, especially marijuana (or herbal cannabis), may be of therapeutic benefit for some patients with rheumatic complaints, a new review published in Arthritis Care & Research, a journal of the American College of Rheumatology, finds scant scientific evidence supporting any use of cannabinoids in rheumatic diseases. Furthermore, not a single controlled study has examined herbal cannabis in the rheumatology patient population.

10 Nov 2015

Astellas enters into definitive agreement to acquire Ocata

Astellas Pharma Inc. and Ocata Therapeutics, Inc., a biotechnology company focused on the research and development of new therapies in the field of regenerative medicine, primarily cell therapy addressing unmet medical needs in ophthalmology patients, announced today that they have entered into a definitive agreement.

10 Nov 2015

New funding for Centenary's life saving research

The Centenary Institute has welcomed the Federal Government’s announcement of funding for 9 new and innovative medical research projects via the latest round of NHMRC grant rounds funding, officially confirmed today.

9 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

St. Jude and Scripps Research Institute scientists help launch Human Dark Proteome Initiative

Scientists at St. Jude Children’s Research Hospital, The Scripps Research Institute (TSRI) and other institutions today announced the launch of the Human Dark Proteome Initiative (HDPI). The initiative aims to accelerate research into biology’s “invisible mass” to provide novel insights into cell function and a new frontier in drug discovery.

9 Nov 2015

First comprehensive genomic and biologic study of top skin disease-causing microbes

An international team of scientists, led by researchers from A*STAR's Genome Institute of Singapore (GIS), Institute of Medical Biology (IMB), and Bioinformatics Institute (BII), and P&G, have completed the first comprehensive genomic and biologic study of all species of Malassezia, one of the top skin disease-causing microbes.

9 Nov 2015

Seven new nCounter PanCancer profiles launched to deeply probe cancer biology

NanoString Technologies, Inc.a provider of life science tools for translational research and molecular diagnostic products, today announced the expansion of its 3D Biology™ portfolio with the commercial launch of the nCounter® PanCancer Profiles, seven new gene expression panels each designed to interrogate a focused area of cancer biology including immuno-oncology.

9 Nov 2015

Key part of MRSA vaccine puzzle unearthed

Immunologists from Trinity College Dublin have unearthed a key piece of the MRSA vaccine puzzle by identifying specific ‘helper’ cells whose role in the immune response is critical in affecting infection outcomes.

9 Nov 2015

NTU Singapore scientists harness dead bacteria to destroy colon tumours cells effectively

Scientists from Nanyang Technological University have successfully used dead bacteria to kill colorectal cancer cells. Harvesting the Clostridium sporogenes bacteria found commonly in soil, the NTU team was able to harness the bacteria in its dead form, and its secretions, to destroy colon tumours cells effectively.

9 Nov 2015

$Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented$

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Takeda Pharmaceutical Company Limited today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015.

6 Nov 2015

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.

6 Nov 2015

Novel genetic therapy treats ‘incurable’ leukaemia

A new treatment that involves editing DNA has been used for the first time at Great Ormond Street Hospital to successfully treat drug-resistant leukaemia.

6 Nov 2015

Seven researchers win 2015 Early Career Researcher UK Awards

The UK is a world-leader in breakthrough scientific discoveries, and seven of the early career researchers leading this field have been recognised for their contributions to areas including malaria elimination, securing water supplies for future generations and empowering patients in the management of their own health care.

6 Nov 2015

City of Hope awarded NIH grant to study potential link between environmental factors and breast cancer

The National Institutes of Health has awarded City of Hope a five-year, $4.8 million grant to study the possible role of chemicals in the environment in the development of breast cancer during the menopausal transition in women.

6 Nov 2015

Stem-cell scientists discover new view of how human blood is made

Stem-cell scientists led by Dr. John Dick have discovered a completely new view of how human blood is made, upending conventional dogma from the 1960s.

6 Nov 2015

Utah chemists devise new way to detect DNA damage

University of Utah chemists devised a new way to detect chemical damage to DNA that sometimes leads to genetic mutations responsible for many diseases, including various cancers and neurological disorders.

6 Nov 2015

Scientists discover small molecule that can block growth of BRCA-deficient cancer cells

Cancer cells with mutations in BRCA1 or BRCA2 genes, which serve a vital role in preserving the integrity of the genetic code, are key targets for cancer therapeutics. Yet, few agents can selectively eliminate cells deficient in BRCA, and none can do so without the risk of inducing drug resistance.

6 Nov 2015

UM SOM Dean E. Albert Reece to be honored with 2015 David E. Rogers Award

The Association of American Medical Colleges announced today that University of Maryland School of Medicine Dean E. Albert Reece, MD, PhD, MBA, will receive the 2015 David E. Rogers Award, which honors a medical school faculty member who has made major contributions to improving the health and health care of the American people. He will be presented the Award on November 8, 2015 at the AAMC's Annual Awards Event.

6 Nov 2015

New study compares effectiveness of clozapine with standard antipsychotics in adults with schizophrenia

In real-world settings, patients with schizophrenia whose symptoms do not respond to standard antipsychotic medications have better outcomes if they are switched to clozapine instead of another standard antipsychotic. They have fewer hospitalizations, stay on the new medication longer, and are less likely to need to use additional antipsychotics.

6 Nov 2015